SERDA Therapeutics Announces Completion of First Phase 1 Clinical Study of SN514.
AMSTERDAM, THE NETHERLANDS, 29 July 2024. SERDA Therapeutics, a biopharmaceutical company focused on developing improved treatments for burns and chronic wounds, today announced completion of its first Phase 1 human clinical study of SN514 hydrogel, an innovative enzymatic wound debriding agent, in healthy adult volunteers. In preclinical studies, SN514 hydrogel showed outstanding efficacy and speed […]
SERDA Therapeutics Announces Initiation of Phase 1 Clinical Study of SN514
AMSTERDAM, THE NETHERLANDS, 03 June 2024. SERDA Therapeutics, a biopharmaceutical company focused on developing improved treatments for burns and chronic wounds, today announced initiation of its first Phase 1 human clinical study of SN514 hydrogel, an innovative enzymatic wound debriding agent, in healthy adult volunteers. SN514 hydrogel is a topical debridement product designed to remove […]
SERDA Therapeutics completes a € 2 Million funding round to develop an innovative enzymatic wound debridement product
Following a successful IND submission, The Dutch health venture SERDA Therapeutics has raised € 2 million in a funding round led by NLC Health Impact Fund. The infusion of new capital will be used to complete Phase I / IIa clinical studies with the company’s innovative wound debridement product SN514. SERDA Therapeutics is developing a […]
SERDA therapeutics submits IND for its lead product, an innovative wound debridement agent.
AMSTERDAM, THE NETHERLANDS, 23 February 2023. SERDA therapeutics, a biopharmaceutical company, announces that it has submitted an Investigational New Drug Application (IND) to the US FDA on the 17th February, 2023 for its lead product SN514 hydrogel, an innovative enzymatic wound debriding agent. Clinical studies are expected to start in Q2 2023. SN514 hydrogel is […]